Compare · DKDCA vs IQV
DKDCA vs IQV
Side-by-side comparison of Data Knights Acquisition Corp. (DKDCA) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DKDCA and IQV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV carries a market cap of $40.51B.
- IQV has hit the wire 5 times in the past 4 weeks while DKDCA has been quiet.
- IQV has more recent analyst coverage (25 ratings vs 0 for DKDCA).
- Company
- Data Knights Acquisition Corp.
- IQVIA Holdings Inc.
- Price
- -
- -
- Market cap
- -
- $40.51B
- 1M return
- -
- -11.59%
- 1Y return
- -
- +7.81%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2013
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest DKDCA
- SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)
- Data Knights Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form SC 13G/A filed by Data Knights Acquisition Corp. (Amendment)
- SEC Form S-1 filed by Data Knights Acquisition Corp.
- Data Knights Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Data Knights Acquisition Corp.
- New insider Casey Paul claimed ownership of 599,172 shares (SEC Form 3)
- New insider Kosasa Thomas claimed ownership of 4,952,409 shares (SEC Form 3)
- SEC Form NT 10-Q filed by Data Knights Acquisition Corp.
- Data Knights Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status
Latest IQV
- Officer Sherbet Eric exercised 8,436 shares at a strike of $131.82, sold $1,239,678 worth of shares (4,446 units at $278.83) and returned $1,112,173 worth of shares to the company (3,990 units at $278.74) (SEC Form 4)
- Director Wims Morris Leslie was granted 125 deferred shares (SEC Form 4)
- Director Goggins Colleen A was granted 144 deferred shares (SEC Form 4)
- Director Fasano Jim was granted 154 deferred shares (SEC Form 4)
- Director Danhakl John G was granted 134 deferred shares (SEC Form 4)
- SEC Form 10-Q filed by IQVIA Holdings Inc.
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Reports Third-Quarter 2026 Results
- IQVIA Selects Veeva Clinical Operations Applications
- IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions